Mirabella (Ethinylestradiol, Gestodene)

Ethinylestradiol and Gestodene, the active ingredients in Mirabella, are a combined oral contraceptive presented as tablets for oral use. It provides reliable pregnancy prevention and can help regulate menstrual cycles in women of reproductive age.

GNH USA supplies Mirabella as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabella, a combined oral contraceptive, works on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

- Contraception: provides reliable prevention of pregnancy when taken as directed. - Menstrual cycle regulation: helps achieve more regular and predictable menstrual bleeding. - Acne improvement: may reduce acne associated with androgen excess in some users.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Spotting: irregular bleeding between periods. - Weight gain: modest fluid retention. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: clot migration to lungs. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe hypertension: sudden high blood pressure. - Liver tumor: benign hepatic adenoma.

Before prescribing Mirabella, clinicians should evaluate individual risk factors and contraindications.

- Assess cardiovascular risk: review history of thrombosis, smoking, hypertension, and age. - Avoid in pregnancy: contraindicated for pregnant women. - Monitor liver function: use with caution in hepatic disease. - Consider drug interactions: be aware of enzyme‑inducing agents that may reduce efficacy. - Counsel on smoking: smoking increases thrombotic risk, especially in women over 35. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Mirabella may interact with several medicines that alter hormone levels or increase thrombotic risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce contraceptive effectiveness. - Certain antiretrovirals (e.g., efavirenz): can lower plasma hormone concentrations. - Additional estrogen therapy (e.g., hormone replacement): increases risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - Some antibiotics (e.g., ampicillin): may slightly diminish efficacy. - Enzyme‑inducing anticonvulsants (e.g., carbamazepine): can lower hormone levels. - Herbal supplements (e.g., St. John’s wort): may reduce contraceptive reliability.